US FDA has accepted a post-approval study plan by Bayer HealthCare for its Essure permanent sterilization device, which is under intense scrutiny in response to adverse events and charges of clinical trial misconduct. The protocol entails a non-randomized, six-year cohort study comparing Essure-implanted women to tubal ligation sterilization subjects.
US FDA plans to continue its review of Bayer HealthCare LLC’s high-profile Essure permanent sterilization device via a six-year long, 2,800-woman, comparative post-approval study.
The study will last six years, but while it is ongoing, “If we see any new evidence that will cause...